Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

Inclusion Criteria: * Written informed consent * Stable chronic renal disease patients receiving hemodialysis 3 times weekly for at least 12 weeks prior to the screening * intact PTH value ≥ 240 pg/mL at the screening * Corrected serum calcium ≥ 8.4 mg/dL at the screening Exclusion Criteria: * Patients with primary hyperparathyroidism * Patients who received cinacalcet within 2 weeks prior to the screening * Patients with change in dose or dosing regimen of active vitamin D/ its analogs, phosphate binders and/or calcium containing compounds within 2 weeks prior to the screening * Patients who received parathyroidectomy and/or parathyroid intervention * Patients with uncontrolled hypertension and/or diabetes * Patients with severe heart disorder * Patients with severe hepatic disease * Patients who take investigational drug in other clinical trial within 12 weeks prior to the screening * Patients who have been judged ineligible to participate in the study by the investigator